Protagonist Therapeutics (PTGX) Reports Q4 Loss of $0.15

Protagonist Therapeutics (NASDAQ: PTGX) reported Q4 EPS of ($0.15), versus ($0.67) reported last year.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Westinghouse said to seek over $50 billion valuation in planned IPO
• Super Micro Computer rises on AI server market optimism